Put Options

15 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q1 2024

May 15, 2024

SELL
$171.37 - $283.23 $291,329 - $481,491
-1,700 Reduced 68.0%
800 $213,000
Q4 2023

Feb 14, 2024

BUY
$120.4 - $237.13 $228,760 - $450,547
1,900 Added 316.67%
2,500 $578,000
Q3 2023

Nov 14, 2023

BUY
$146.04 - $225.78 $14,604 - $22,578
100 Added 20.0%
600 $87,000
Q2 2023

Aug 14, 2023

BUY
$203.88 - $312.0 $40,776 - $62,400
200 Added 66.67%
500 $115,000
Q1 2023

May 15, 2023

SELL
$231.06 - $307.08 $1.34 Million - $1.78 Million
-5,800 Reduced 95.08%
300 $72,000
Q4 2022

Feb 14, 2023

SELL
$58.39 - $296.54 $4.92 Million - $25 Million
-84,300 Reduced 93.25%
6,100 $1.77 Million
Q3 2022

Nov 14, 2022

BUY
$60.57 - $79.51 $5 Million - $6.57 Million
82,600 Added 1058.97%
90,400 $5.88 Million
Q2 2022

Aug 08, 2022

BUY
$58.04 - $100.2 $412,084 - $711,420
7,100 Added 1014.29%
7,800 $558,000
Q1 2022

May 16, 2022

BUY
$55.89 - $101.89 $39,123 - $71,323
700 New
700 $69,000
Q4 2020

Feb 16, 2021

SELL
$110.06 - $133.7 $1.84 Million - $2.23 Million
-16,700 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$99.78 - $124.21 $1.38 Million - $1.71 Million
13,800 Added 475.86%
16,700 $1.98 Million
Q2 2020

Aug 14, 2020

BUY
$60.13 - $125.71 $174,377 - $364,559
2,900 New
2,900 $328,000
Q1 2020

May 15, 2020

SELL
$66.76 - $93.49 $166,900 - $233,725
-2,500 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$84.28 - $118.5 $42,140 - $59,250
500 Added 25.0%
2,500 $228,000
Q1 2019

May 15, 2019

BUY
$103.48 - $143.84 $206,960 - $287,680
2,000 New
2,000 $251,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.42B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Walleye Trading LLC Portfolio

Follow Walleye Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.